



zentek

Corporate Presentation
February 2023

NASDAQ: ZTEK

TSXV: ZEN

Forward-Looking Statement & Disclaimer



This presentation is being provided for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of Zentek Ltd. ("**Zentek**" or the "**Company**") in Canada, the United States or any other jurisdiction. Trading in the securities of the Company should be construed as highly speculative. This presentation is not, and in no circumstances is it to be construed as, a prospectus, an offering memorandum, an advertisement, or a public offering of securities. No securities regulatory authority or similar authority has reviewed or in any way passed upon the document or the merits of any securities of the Company and any representation to the contrary is an offence. Except as otherwise stated, information included in this presentation is given as of the date hereof. The delivery of this presentation shall not imply that the information herein is correct as of any date after the date hereof. Readers should not construe anything in this presentation as investment, legal or tax advice. Each recipient should consult its own investment, legal, tax and other advisers regarding the financial, legal, tax, and other aspects of the Company, including whether it is legally permitted to purchase any securities from the Company under applicable laws. The securities of the Company have not been and may not be registered under the United States *Securities Act of 1933*, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered and sold in the United States or to, or for the account or benefit of, U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

All dollar amounts referenced herein, unless otherwise indicated, are expressed in US dollars.

No information contained in this presentation constitutes medical advice, and it is not to be used for treatment purposes, or to replace consultation with a qualified medical professional. No information contained herein is intended to diagnose health problems or to take the place of professional medical care. The information contained herein is neither intended to dictate what constitutes reasonable, appropriate or best care for any given health issue, nor is it intended to be used as a substitute for the independent judgment of a physician for any given health issue. All content, including text, graphics, images and information, contained herein is for general information purposes only.

Opinions and estimates disclosed constitute management's judgment and are subject to change without notice, as are any statements of financial market trends, which are based on current market conditions. Management of Zentek does not warrant the accuracy or completeness of the information contained herein.

The presentation may include, in some cases, estimates, projections, forecasts, plans, budgets and similar materials and information regarding or relating to the future operating and financial performance or prospects of Zentek and other anticipated events or results that are not historical facts (collectively, "Forward-Looking Information"). Forward-Looking Information can often be identified by words such as "will", "may", "estimate", "expect", "plan", "project", "intend", "anticipate" and other words indicating that the statements are forward-looking. Forward-Looking Information in this presentation includes, without limitation, estimates and statements with respect to Zentek objectives and goals, to the effect that Zentek or management expects a stated condition or result to occur, regulatory approvals, the adequacy of financial resources, business plans and strategy, and other events or conditions that may occur in the future. All Forward-Looking Information is subject to risks, uncertainties, estimates and assumptions, including the risks described in the Company's public filings with securities commissions or similar regulatory authorities in Canada which are available on the System for Electronic Document Analysis and Retrieval ("SEDAR"). Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Accordingly, there can be no assurance that Forward-Looking Information will be realized. Zentek does not warrant or guarantee the Forward-Looking Information in any way. All of the Forward-Looking Information in this presentation is qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management of the Company believes that the expectations conveyed by Forward-Looking Information herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such Forward-Looking Information. The Company undertakes no obligation to update any Forward-Looking Information, even if new information becomes available as a result of future events or if circumstances or management's estimates or opinions should change or for any other reason, except as required by applicable securities laws. The Forward-Looking Information contained herein is presented for the purposes of assisting readers in understanding the Company's plan, objectives and goals and may not be appropriate for other purposes.

To the extent any Forward-Looking Information in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable securities laws, such information is being provided to demonstrate the impact to the Company with potential market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with Forward-Looking Information generally, are, without limitation, based on the assumptions and subject to the risks set out above. The Company's actual financial position and results of operations may differ materially from management's current expectations. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual financial position or results of operations.


The Forward-Looking Information contained herein was prepared by the management of the Company based on information available at the time the presentation was prepared. Unless otherwise stated, information in this presentation is as of February 24, 2023.

This presentation may contain certain financial performance measures that are not recognized or defined under International Financial Reporting Standards ("IFRS"), which measures are "Non-GAAP Measures". As a result, this data may not be comparable to data presented by other companies. The Company believes that any Non-GAAP Measures included in this presentation are useful indicators of performance and are specifically used by management to assess the current and future performance of the Company. Non-GAAP Measures should be considered together with other financial information prepared in accordance with IFRS to enable readers to evaluate the Company's performance and prospects in a manner similar to the Company's management. Accordingly, any Non-GAAP Measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

No representation, warranty or guarantee, expressed or implied, is made by Zentek or any of its representatives with respect to the accuracy or completeness of any information provided in this presentation. No person is entitled to rely on the accuracy or completeness of this information. Any third party information contained herein has not been independently verified. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted bylaw), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any person. Readers should consult with their own professional advisors regarding their particular circumstances and the Company assumes no liability for any consequences to the investor of any investment in the Company's securities. Neither Zentek, nor its directors, officers, employees, shareholders or agents shall be liable for any claims, expenses, damages (including direct, indirect, special or consequential damages), loss of profits, or opportunities arising from the use of or reliance on the information contained in this presentation.

Zentek Ltd. is an IP development and commercialization company focused on next-generation nanotechnologies that improve people's lives.

SUSTAINABLE DEVELOPMENT GOALS




- ✓ Scalable with differentiated opportunities
- ✓ Health Canada Authorization for ZenGUARD™, our first commercial product
- ✓ Working with Universities and tech partnerships

NASDAQ: ZTEK

- \$180M market capitalization
- No debt
- Completed capital raise of ~US\$26M in January 2022
- **Nasdaq trading commenced on March 22, 2022**

	ZTEK	ZEN
Exchange	NASDAQ	TSXV
Recent Price	\$1.54 (a/o 2/22/23)	C\$2.07 (a/o 2/22/23)
52 Wk. Range	\$1.28 - \$3.78	C\$1.72- C\$4.70
Market Cap	~\$153M (a/o 2/22/23)	~C\$205M (a/o 2/22/23)
Avg Daily Vol	~25.5K	~145K
Shares O/S	99.1M (~106.6M FD)	
Insider Ownership	3.9%	
Institutional Ownership	0.03%	
Debt to Capital	0%	

Our Business Model



Commercialization opportunities now with
robust IP development pipeline for the future



ZenGUARD™ for PPE surgical masks, and potentially other PPE, HVAC and other markets



IP pipeline in areas of health and advanced materials




zenGUARD™

ZenGUARD™ – What is it?



- ✓ Broad-Spectrum Antimicrobial Coating – has shown to be 99%+ effective*
- ✓ ASTM Level 3, exceeds the highest standard specifications**
- ✓ Rigorously tested and safe, patented technology
- ✓ Only graphene-coated surgical mask Authorized by Health Canada
- ✓ **Focusing on other applications for ZenGUARD™, including HVAC filters to improve indoor air quality**



- ① Hydrophobic exterior – Prevents infectious droplets from penetrating mask
- ② **ZenGUARD™ antimicrobial layer – Filters dangerous pathogens**
- ③ Melt-blown layer – Filters dust and other particles
- ④ Hydrophilic interior – Traps droplets inside mask to prevent transmission

*Source: SGS Test Report No: ASH22-063805-01 Polypropylene Nonwoven Fabrics AgGO Coated Spunbond

**Source: ASTM International ASTM F2100-20. Standard Specification for Performance of Materials Used in Medical Face Masks.

Testing, Validation, Authorization
Pathway with various testing facilities
and the Government of Canada

- ✓ **Rigorous testing** across multiple disciplines and applications
- ✓ **21 partners** - Two years of research, testing, and validation
- ✓ **Significant opportunity** for application in many other high-risk settings



As Zentek seeks to gain access to new markets, reliable, high-capacity and high-quality production with additional sales channels are crucial to our global success.

- Viva Healthcare Packaging Ltd. (Canada)
- Southmedic (Canada)
- EkoMed (Turkey) – 120 customers in countries worldwide.
- GMAF – (Denmark) recyclable mask



Cost of Hospital Associated Infections* (HAIs)



\$28.4B

(Direct medical costs per year in US hospitals)



\$12.4B

(Cost to society from early deaths and lost productivity)



\$25K

(Estimated HAI Cost per infection)




5-10%

(Develop an HAI during hospital stay)

Typical ASTM Level 3, 3-ply Surgical Mask


Seasonal Flu



Tuberculosis



SARS-CoV-2



zenGUARD™

Antimicrobial Coating

VS



Filters out **98.9% more bacteria** and **97.8% more virus particles** compared to a typical ASTM Level 3, 3-ply uncoated mask




ZenGUARD™ can inhibit a variety of gram-positive and gram-negative antimicrobial-resistant (AMR) pathogens associated with difficult to treat clinical infections at very low concentrations*

Gram Negative

- ✓ Serratia marcescens
- ✓ Pseudomonas aeruginosa (1)
- ✓ Pseudomonas aeruginosa (2)
- ✓ E. coli (ESBL)
- ✓ E. coli (CRO)
- ✓ Klebsiella pneumoniae (ESBL)
- ✓ Klebsiella pneumoniae (CRO)
- ✓ Enterobacter aerogenes
- ✓ Stenotrophomonas maltophilia

zenGUARD™



Gram Positive

- ✓ HA-Methicillin Resistant Staphylococcus aureus (MRSA)
- ✓ CA-Methicillin Resistant Staphylococcus aureus (MRSA)
- ✓ Vancomycin Resistant Enterococcus faecium (VRE)
- ✓ Penicillin-resistant Streptococcus pneumoniae

To help address the problem of HAIs, our initial focus is ZenGUARD™ for surgical masks while we develop other PPE (gowns, caps, gloves etc.) and air filtration applications (HVAC filters)



Health Canada
Authorized

> US \$52B¹
Personal Protective Equipment
(PPE)



ZenGUARD™ on masks,
respirators and potentially other PPE to
help protect front-line workers, the
public and reduce spread of pathogens
(including and beyond COVID-19)

> US \$66B²
Indoor Air Quality



ZenGUARD™ potentially used on
air filters to filter airborne
pathogens in homes, schools,
hospitals and commercial/
industrial spaces

¹ Source: 2019 estimate per fortunebusinessinsights.com; over \$90B in 2027

² Source: 2020 global HVAC filter estimate of US \$12.9B per fortunebusinessinsights.com; 2020 US furnace filter market estimated at US \$21.3B per researchandmarkets.com. Management estimates US represents 40% of global furnace filter demand for illustrative purposes only


ZenGUARD™ - HVAC Testing & Development

zentek

- Awarded Innovative Solutions Canada (ISC) Testing Stream contract and testing with the National Research Council (NRC)
- Successfully Completed Phase 2 testing:
 - Modular classroom environment – Completed with NRC and ISC
 - **OBJECTIVE MET:** to demonstrate a reduction in live airborne surrogate contamination within a real-world operational environment
 - **EFFECTIVE:** **Significant reduction in airborne bacterial and viral load** compared to equivalent MERV-rated uncoated filters using a bacteriophage (a SARS-COV-2 surrogate).
 - **SAFE:** **No shedding of ZenGUARD™ material** in the air stream
 - **EFFICIENT:** **Insignificant impact to air flow**, less energy consumed than if using a higher rated, uncoated filter



zenGUARD™



WHY SIMPLICITY MATTERS

Improving filtration and reducing airborne pathogens on the most common air filters used today can have a significant global impact on safety, energy and livelihood

- ✓ **Deactivate pathogens** on the surface of HVAC filters
- ✓ **Reduction in airborne pathogens** post filter compared to uncoated filters
- ✓ **Insignificant impact to air flow, less energy consumed than if using a higher rated, uncoated filter**
- ✓ **Easily applied** to current & common filter material
- ✓ **Uses existing HVAC infrastructure – no new equipment, no capital spend**

ZenGUARD™ – Reliable Supply



- ✓ Soon to be commissioned antimicrobial coating production and application facility in Guelph, Ontario
- ✓ Grand Opening June 2022
- ✓ 26,000 square feet
- ✓ 26 tonnes capacity per year
- ✓ Capable of producing up to 720 million mask equivalent per month
- ✓ Internal and third-party coating application capacity to be operational in Fiscal Q1 2024
- ✓ Recently signed agreement with Viva Healthcare, a large surgical mask manufacturer in Canada



Zentek develops and commercializes IP for next-gen, nanotechnology-enabled solutions
IP pipeline with scalable commercialization opportunities



- Building on Health Canada authorization of ZenGUARD™ enhanced masks
- Potential further commercialization of ZenGUARD™ coating for PPE markets & Indoor Air Quality market



- Continuing to develop high-impact, commercially attractive applications
- Existing and growing sustainability-focused IP pipeline in the areas of advanced materials and clean tech



Why Invest?

- ✓ Near term revenue generation with ZenGUARD™
- ✓ Highly attractive upside optionality with potential new products based on our IP

zentek

Thank you!

Greg Fenton, CEO
gfenton@zentek.com

Ryan Shacklock, Investor Relations
rshacklock@zentek.com



Facebook - facebook.com/zentekltd



LinkedIn - linkedin.com/company/zentekltd/



Twitter - twitter.com/zentekltd



Instagram - instagram.com/zentekltd



YouTube - youtube.com/c/zentekltd



APPENDIX



Greg Fenton - *Chief Executive Officer, Director*

Seasoned investment professional, with a Bay Street career spanning nearly 30 years. He has worked in various capacities with ever-increasing responsibility in both the Canadian banking and investment management sectors. Greg has been a partner in three investment management firms, heading the Risk Solutions Group at Scotiabank and leading Liability Driven Investment Group at National Bank Financial. His experience spans many disciplines: capital markets, investment management, actuarial, pension, insurance, accounting, tax and risk management.



Dr. Francis Dubé - *Executive Chairman, Director*

An entrepreneurial mindset with a science and healthcare background, Francis brings a leadership that is inclusive and leads to strong team building with a focus on success. Previously, Francis was a director and Co-founder of Cannacure Corp., a private cannabis company that he saw to a successful buyout. Francis has significant experience in strategic planning, fundraising and capital markets.



Brian Bosse - *Chief Operations Officer, Director*

Brian has been a respected professional investor for nearly 30 years with corporate capital allocation policy being his key business specialty. Formerly Brian served Dundee Corporation's Goodman & Company Investment Counsel as portfolio manager of the Goodman Bluespring Fund. He earned an honors degree from the Lazaridis School of Business and Economics in Waterloo, Ontario plus the Chartered Financial Analyst designation. Brian joined Zentek in May 2018 as director and officer following a successful proxy battle.



Wendy Ford - *Chief Financial Officer*

Wendy has more than three decades of experience in finance and accounting leadership roles for both private and publicly traded companies. Most recently, Ms. Ford served as VP of Finance and CFO of Mancor Industries, a precision manufacturer of metal components and sub-assemblies. Prior to this, Ms. Ford served as CFO of AirBoss of America, a publicly traded company on the TSX, focused on the compounding, defense, and automotive industries. She has served in leadership roles including financial reporting, auditing, taxation, and compliance for Nasdaq and TSX listed companies. Ms. Ford is a Chartered Professional Accountant (CPA) and is a graduate of the University of Toronto.



Peter Wood – *VP, Special Projects*

Peter Wood is a geological engineer with over 35 years' exploration and project management experience in the mining industry. During this time, he has worked with several major mining companies including Newmont, Homestake, and HudBay and has also been actively involved in the exploration and development of gold, base metal, platinum-group element, and magmatic nickel-copper deposits with many junior exploration companies. Peter graduated from the University of Toronto with an Honours BSc in Geological Engineering in 1983 and an MSc in Geology in 1987. He joined the Zentek team as Vice President, Exploration in January 2013.



Ryan Shacklock – *VP, Strategy, Business Development, & Investor Relations*

Prior to leading Zentek's Business Development and Investor Relations efforts, Ryan spent nearly 15 years working in large public companies, most recently with Nutrien Ltd. (formerly Potash Corporation of Saskatchewan Inc.) where he held a number of positions of growing responsibility in Investor Relations, Risk Management, Corporate and Sustainability Reporting, Treasury, Internal Control Compliance and Finance Transformation. Ryan is a graduate of the University of Saskatchewan, a Chartered Professional Accountant and Certified Treasury Professional.



Dr. Colin van der Kuur – *VP, Science and Research*

Dr. Colin van der Kuur, B. Sc., M. Div., D. Min. was the first graduate from the University of Guelph with a Specialized Honours in chemical physics in 1993 and subsequently completed a doctorate in leadership in 2010. He worked in the non-profit industry for 25 years including serving as the Director of Church Planting for the Fellowship Pacific where he trained and coached executives. Through his leadership, Zentek is rapidly expanding a high-value IP portfolio through internal research, collaboration and licensing world-leading technology.



Greg Fenton - *Chief Executive Officer, Director*

Seasoned investment professional, with a Bay Street career spanning nearly 30 years. He has worked in various capacities with ever-increasing responsibility in both the Canadian banking and investment management sectors. Greg has been a partner in three investment management firms, heading the Risk Solutions Group at Scotiabank and leading Liability Driven Investment Group at National Bank Financial. His experience spans many disciplines: capital markets, investment management, actuarial, pension, insurance, accounting, tax and risk management.



Dr. Francis Dubé - *Executive Chairman, Director*

An entrepreneurial mindset with a science and healthcare background, Francis brings a leadership that is inclusive and leads to strong team building with a focus on success. Previously, Francis was a director and Co-founder of Cannacure Corp., a private cannabis company that he saw to a successful buyout. Francis has significant experience in strategic planning, fundraising and capital markets.



Brian Bosse - *Chief Operations Officer, Director*

Brian has been a respected professional investor for nearly 30 years with corporate capital allocation policy being his key business specialty. Formerly Brian served Dundee Corporation's Goodman & Company Investment Counsel as portfolio manager of the Goodman Bluespring Fund. He earned an honors degree from the Lazaridis School of Business and Economics in Waterloo, Ontario plus the Chartered Financial Analyst designation. Brian joined Zentek in May 2018 as director and officer following a successful proxy battle.



Frank Klees - *Director*

Frank Klees is a highly respected professional who has held senior leadership positions in both the government and private sector. Frank served five terms as a Progressive Conservative Member of the Government of Ontario from 1995 to 2014. He held senior cabinet positions in the governments of Mike Harris and Ernie Eves including Ministers of Transportation and Tourism, Chief Government Whip and Deputy House Leader with additional responsibilities as a Member of the Management Board of Cabinet and the Board of Internal Economy. During 19 years as an elected official, Frank established strong and trusted working relationships at all levels of government. He has extensive business experience in the energy sector, financial services, and real estate development. He was a co-founder and Executive VP of Municipal Gas Corporation, served as Director and Member of the Audit and Governance Committees of Universal Energy Ltd. and was a member of the Supervisory Board of Rockwool North America since 2003. Frank is a Sr Advisor to several public and private enterprises. He provides business development, government relations, and strategic advisory services.



Eric Wallman - *Director*

Eric Wallman is a graduate of the University of Manitoba in 1983 and obtained a full CA designation in 1986. He has held senior accounting and finance positions in industry since 1991 and has been an active investor in the junior mining market since 1992. Currently, Eric is the Senior Vice-President, Finance and Administration with Bothwell Cheese, the largest independently owned cheese manufacturer in Canada. His role includes strategic planning for Bothwell Cheese and two related companies. Mr. Wallman is also an active board member of the Western Dairy Council.

Ilse Treurnicht - *Director*



Ilse Treurnicht's career spans scientific research and commercialization, building health and cleantech firms, venture and impact capital, and public policy. She is managing partner of TwinRiver Capital (an impact investment firm), a general partner at North South Ventures (a seed stage med fund), chair of the Public Policy Forum and a director of the Equality Fund. Ilse was CEO of MaRS Discovery District in Toronto from 2005-2017 as it developed from a nascent organization into a leading urban innovation hub. She joined MaRS from her role as CEO of Primaxis Technology Ventures, a seed stage venture capital firm (1999-2005). She was chair of the Canadian Task Force on Social Finance (2010), served on the Government of Canada's Science, Technology and Innovation Council (2014-2016), Canada's Advisory Council on Economic Growth (2016-2019), and the Advisory Committee on Open Banking (2018-2021), as well as the boards of several technology firms and non-profit organizations. Ilse holds a doctorate in chemistry from Oxford University, which she attended as a Rhodes Scholar.



Dr. Yingfu Li - *Professor in the Department of Biochemistry and Biomedical Sciences*

Dr. Li is a Professor in the Department of Biochemistry and Biomedical Sciences at McMaster University. He earned a Ph.D. in Biochemistry from Simon Fraser University, where he discovered a DNA molecule that catalyzes porphyrin metalation, which won him the Governor General Academic Gold Medal and Natural Sciences and Engineering Research Council of Canada Doctoral Prize. He was awarded a Medical Research Council of Canada postdoctoral fellow and carried out his postdoctoral research at Yale University where he studied a series of catalytic DNA molecules for DNA phosphorylation, DNA capping and DNA ligation. Dr. Li's addition to our Advisory Board ensures his knowledge, experience and advice will continue to help the Company bring this highly differentiated and scalable rapid detection platform to market.



Dr. Joseph Armand Korkis - *Board-Certified Otolaryngologist*

Dr. Korkis is a board-certified Otolaryngologist and Head and Neck surgeon. He is a graduate of the Royal College of Surgeons in Ireland and spent 9 years in post-graduate studies in Ireland and Canada. He is the assistant Clinical Professor in the department of Otolaryngology and Head and Neck surgery at McMaster University. Dr. Korkis' experience and advice – along with that of Dr. Li and Dr. Ken Reed, a Harvard trained dermatologist as announced on June 30, 2021 – is expected to add tremendous value as ZEN continues to execute on its health care strategy



Ravi Kaza - *Advisor*

Mr. Kaza graduated from The Wharton School of the University of Pennsylvania with a BS in Finance Summa Cum Laude at age 19 and has spent the last 25 years consistently focused on disruptive technologies. He started his career in Silicon Valley at a prominent investment banking group founded by Frank Quattrone where he worked on numerous transactions involving companies such as Amazon, Apple, Northern Telcom, and Lam Research. Mr. Kaza then entered the money management business as a Vice President at Pequot Capital Management, at the time one of the world's largest alternative asset managers with a focus on technology investing. He was then hired by Stanley Druckenmiller as a Managing Director at Duquesne Capital Management to focus primarily on technology investing.

In 2003, Mr. Kaza founded Seasons Capital Management, which he helped grow into a multi-billion-dollar alternative investment manager that oversaw several technology-related investment strategies. In 2010, Mr. Kaza shifted his focus to running primarily internal capital with a continued primary focus on disruptive technologies. Consistent with this focus, Mr. Kaza was introduced to the Zentek management team during the Summer of 2021, when he became a shareholder.



Kenneth Reed - *M.D.*

Kenneth Reed, M.D. is a board-certified dermatologist in private practice and serves as a scientific advisor to several innovative biotechnology companies. After completing a residency at the Harvard-MGH combined dermatology program, he established a clinical practice in a Boston suburb, DermAsap, and has continued as a principal investigator for a number of biopharmaceutical companies. He currently serves on the board of directors of Red Hill Biopharma and Minerva Biotechnologies. Dr. Reed is also a cofounder of Early Cell, a company focused on early detection of circulating fetal cells, and Lispiro LLC, which focuses on idiopathic pulmonary fibrosis, and age-related disorders.